X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    A Breakthrough Medication For Dystonia Is Being Developed

    Australia Introduces A New Tool To Lower Medicine Costs

    Dupixent Charts A Win Before The FDA Prurigo Nodularis Order

    Hong Kong University Creates Bone Anabolic Aptamer Drug

    Developing Drugs That Target Multidrug-Resistant Bacteria

    Persistent Bacteria Are Undermining Antibiotic Treatment

    First Treatment For Advanced ASPS Is Given The Green Light

    Usual Pharma Compliance Issues Noted In FDA Warning Letters

    FDA Drug Nods In 2022 Fall To 37 From 51 Average Since 2017

    New Method Finds The Most Effective Cure For Breast Cancer

    New Method May Stop Antibody From Rejecting Transplant Cells

    Global Alliance Finds Genetic Cause of Neurological Disease

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    A Breakthrough Medication For Dystonia Is Being Developed

    Australia Introduces A New Tool To Lower Medicine Costs

    Dupixent Charts A Win Before The FDA Prurigo Nodularis Order

    Hong Kong University Creates Bone Anabolic Aptamer Drug

    Developing Drugs That Target Multidrug-Resistant Bacteria

    Persistent Bacteria Are Undermining Antibiotic Treatment

    First Treatment For Advanced ASPS Is Given The Green Light

    Usual Pharma Compliance Issues Noted In FDA Warning Letters

    FDA Drug Nods In 2022 Fall To 37 From 51 Average Since 2017

    New Method Finds The Most Effective Cure For Breast Cancer

    New Method May Stop Antibody From Rejecting Transplant Cells

    Global Alliance Finds Genetic Cause of Neurological Disease

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

Significant M&A Agreements Are On The Horizon For 2023

Content Team by Content Team
10th January 2023
in Facilities & Operation, News

According to EY’s 2023 M&A Firepower report, the life sciences sector has record levels of deal-making Firepower, which measures a company’s ability to undertake M&A on the strength of its balance sheet.

M&A activity worldwide in 2022

In the first eleven months of 2022, the total value of life sciences mergers and acquisitions (M&A) investments reached $105 billion, a significant decrease from 2021. The study discovered that this trend changed as the year came to a conclusion, as Johnson & Johnson and Amgen each made multibillion dollar purchases.

According to EY’s analysis, global M&A investment is expected to decline overall by 2022. This, according to the report, indicates the persistent economic concerns brought on by geopolitical pressure. With Pfizer’s takeover of Biohaven, the single largest deal up to December 2022, the value of biopharma M&A fell by 42% in the first 11 months of 2022 compared to 2021. In 2022, alliances played a crucial role in the M&A strategies of biopharma companies.

The research revealed that smaller companies’ valuations have plummeted and that the volume of initial public offerings (IPOs) and special purpose acquisition companies (SPACs) has sharply decreased. As a result, tiny biotechs have fewer possibilities for obtaining public money, which gives them more reason to look for an acquisition as a means of exiting the market.

Beginning in December 2022, the biopharma industry alone possessed deal-making Firepower worth over $1.4 trillion. However, the report emphasised that the industry also has essential strategic reasons to seek acquisitions, with lower deal premiums serving as an incentive to spend that capital.

The report hypothesised that Amgen’s move to purchase Horizon Therapeutics for over $28 billion in December may indicate that the market is prepared to resume making larger transactions in 2023.

M&A forecasts for 2023

It was found that the top companies in the market will experience growth gaps over the following five years as a wave of market-dominating biopharmaceuticals lose their patent exclusivity and compete with less expensive generic and biosimilar goods.

With the life sciences industry currently experiencing an innovation renaissance, EY found that there are several possible acquisition prospects. A sizable clinical pipeline of cell and gene therapies as well as the mRNA platform, which provided vaccinations against COVID-19, are examples of this development.

Artificial intelligence (AI) and digital technology advancements give businesses the chance to provide better, more individualised care through remote and virtual channels, according to EY. This industry’s potential was acknowledged in the report as it advances toward becoming an intelligent health ecosystem that is increasingly interconnected and data-driven.

Although biopharma businesses have been acting conservatively regarding their M&A activity for the majority of 2022, the proper acquisitions are still being completed, according to EY Global Deals Leader, Life Sciences, Subin Baral. With rising interest rates, inflation, and the effects of US legislation like the Inflation Reduction Act, financing mergers and acquisitions has become more difficult. Companies may release their Firepower in the upcoming 12 months in the longer perspective, continued Baral, not simply to bring new ideas into their catalogues but to harness the tech and data tools that can overhaul and strengthen their entire operating models.

According to EY’s 2023 M&A Firepower research, there are three key ways businesses may maximise the advantages of deal-making in 2023:

  • De-risk transactions as much as they can.
  • Recognize the kinds of transactions that have been profitable in the past and why.
  • Ensure that the proper procedures are in place for integrating new acquisitions.

M&A will need to play a prominent strategic role as companies strive to ensure expansion and safeguard their business strategies amid a rising flood of innovation, Baral said.

Previous Post

A Breakthrough Medication For Dystonia Is Being Developed

Related Posts

Drug Development

A Breakthrough Medication For Dystonia Is Being Developed

6th January 2023
News

Australia Introduces A New Tool To Lower Medicine Costs

6th January 2023
News

Inflation Is Pharma Executives Top Challenge In 2023- Poll

6th January 2023
Dupixent Charts A Win Before The FDA Prurigo Nodularis Order
Drug Development

Hong Kong University Creates Bone Anabolic Aptamer Drug

5th January 2023
Facilities & Operation

Cancer Treatment Rates In NHS Hit An All-Time High In 2022

5th January 2023
Developing Drugs That Target Multidrug-Resistant Bacteria
News

Persistent Bacteria Are Undermining Antibiotic Treatment

5th January 2023

Latest News

Facilities & Operation

Significant M&A Agreements Are On The Horizon For 2023

10th January 2023
Drug Development

A Breakthrough Medication For Dystonia Is Being Developed

6th January 2023
News

Australia Introduces A New Tool To Lower Medicine Costs

6th January 2023
News

Inflation Is Pharma Executives Top Challenge In 2023- Poll

6th January 2023
Dupixent Charts A Win Before The FDA Prurigo Nodularis Order
Drug Development

Hong Kong University Creates Bone Anabolic Aptamer Drug

5th January 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In